INT202473

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.31
First Reported 2007
Last Reported 2008
Negated 0
Speculated 0
Reported most in Body
Documents 3
Total Number 4
Disease Relevance 2.43
Pain Relevance 0

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Cd19 (Mus musculus)
Pain Link Frequency Relevance Heat
Inflammation 18 5.00 Very Low Very Low Very Low
cytokine 12 5.00 Very Low Very Low Very Low
chemokine 8 5.00 Very Low Very Low Very Low
methotrexate 6 5.00 Very Low Very Low Very Low
dexamethasone 6 5.00 Very Low Very Low Very Low
vincristine 6 5.00 Very Low Very Low Very Low
Inflammatory mediators 4 5.00 Very Low Very Low Very Low
Central nervous system 2 5.00 Very Low Very Low Very Low
anesthesia 2 5.00 Very Low Very Low Very Low
intrathecal 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Lymphatic System Cancer 170 94.72 High High
Chronic Lymphoid Leukemia 28 89.32 High High
Multiple Myeloma 16 72.80 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 8 68.40 Quite High
Htlv Types I And Ii 10 68.20 Quite High
Disease 78 68.00 Quite High
Mantle-cell Lymphoma 26 58.44 Quite High
Follicular Lymphoma 26 57.40 Quite High
Cancer 30 46.76 Quite Low
Infection 180 5.00 Very Low Very Low Very Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Cells were stained with PE-conjugated anti-CD19 at 5 ?
CD19 Binding (stained) of
1) Confidence 0.31 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1781481 Disease Relevance 0 Pain Relevance 0
Cells were labeled with CD19 conjugated to PE, 5 ?
CD19 Binding (conjugated) of
2) Confidence 0.31 Published 2007 Journal PLoS Pathogens Section Body Doc Link PMC1781481 Disease Relevance 0 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD19 Binding (targeting) of
3) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.22 Pain Relevance 0
Antibodies targeting CD19, CD20, CD22, in combination with a toxin, CD23, CD40, CD80, and HLA-DR are being evaluated in clinical trials, and their additional benefit will be evaluated in coming years (DiJoseph et al 2004, 2006; Byrd et al 2005; Czuczman et al 2005; Foreno-Torres et al 2006).
CD19 Binding (combination) of
4) Confidence 0.18 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727901 Disease Relevance 1.21 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox